GeminIQ Website Logo

Viewing AKTX free

Subscribe for full history, 50+ metrics, screener, watchlist...

Akari Therapeutics Plc

AKTX

Companies in Pharmaceutical Preparations

Akari Therapeutics Plc (AKTX) — SEC Financial Statements & Analysis

Akari Therapeutics Plc (AKTX) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Assets
Cash And Cash Equivalents At Carrying Value
30-3302414
Assets Current
Assets Current
4533333534
Cash
352-332---
Restricted Cash
000000---0
Prepaid Expense Current
1000100110
Other Assets Current
0000000000
Intangible Assets Net Excluding Goodwill
---------0
Goodwill
-88888----
Other Intangible Assets Net
303434393939----
Assets
3448455151513534
Liabilities And Stockhold…
Accounts Payable Current
99111213125532
Liabilities Current
Accrued Liabilities Current
3222333222
Liabilities Current
1312161721209965
Convertible Debt
111111----
Notes Payable Current
000001----
Other Liabilities Current
1001000110
Derivative Liabilities Noncurrent
-00-------
Other Liabilities Noncurrent
-00000----
Deferred Income Tax Liabilities Net
677888----
Liabilities
202023252928---5
Common Stock Value
--77652221
Additional Paid In Capital
235234224221216213183183176175
Stockholders Equity
Stockholders Equity
142823262222-7-4-4-0
Accumulated Other Comprehensive Income Loss Net Of…
-1-1-1-1-1-1-1-1-1-1
Retained Earnings Accumulated Deficit
-279-265-259-253-251-247-243-241-233-227
Liabilities And Stockholders Equity
3448455151513534
Common Stock Par Or Stated Value Per Share
0000000000
Common Stock Shares Authorized
381381331331368368338338338338
Common Stock Shares Issued
229226228228231239243243240238
Shares Outstanding
229226228228231239243243240238

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
2026258.29%271.12%----------
2025-8.74%-13.33%-25.19%-16.68%-6.82%-23.70%-34.81%-44.23%-54.81%19.83%277.48%126.03%
202452.74%96.58%151.71%-9.58%-25.00%-31.94%-38.03%-22.61%-21.02%5.09%2.75%-2.42%

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Performance and Valuation Metrics

Metrics
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
0.27
0.44
0.19
0.19
0.16
0.15
0.29
0.58
0.44
0.95
Quick Ratio
0.21
0.43
0.17
0.17
0.13
0.14
0.25
0.49
0.24
0.88
Working Capital
-9.83M
-6.89M
-12.62M
-13.84M
-17.56M
-16.96M
-6.69M
-3.70M
-3.55M
-243.00K
Leverage & Debt
Debt to Equity
1.36
0.69
1.00
0.99
1.34
1.27
-1.41
-2.37
-1.78
-20.02
Interest Coverage TTM
-30.90
-18.20
-55.22
-49.83
-64.14
-88.70
-136.38
-339.02
-3,470.21
-11.19
Debt Ratio
0.58
0.41
0.50
0.50
0.57
0.56
3.45
1.73
2.28
1.05
Efficiency & Turnover
Asset Turnover TTM
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Per Share Metrics
Diluted EPS TTM
-0.47
-0.26
-0.24
-0.19
-0.33
-0.41
-0.33
-0.29
-0.09
-0.82
Free Cash Flow Per Share TTM
-0.18
-0.16
-0.15
-0.14
-0.20
-0.26
-0.21
-0.29
-0.34
-0.15
Dividend Per Share TTM
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Growth Metrics
Net Income Growth (1Y)
56.43%
-12.60%
-1.54%
-23.85%
251.06%
-59.01%
-65.63%
-64.45%
-89.53%
-
EPS Growth (1Y)
43.81%
-37.98%
-26.49%
-31.64%
246.07%
-49.60%
-60.16%
-65.70%
-89.04%
-
Valuation Metrics
P/E TTM
-10.90
-44.99
-167.33
-240.14
-151.01
-117.80
-359.27
-378.85
-785.99
-151.83
P/B
21.27
27.48
116.33
115.05
124.51
104.88
-859.74
-1,648.13
-1,129.87
-32,008.68
Market Cap
305.80M
778.31M
2.64B
2.95B
2.71B
2.33B
5.76B
6.10B
4.01B
7.33B
Enterprise Value
303.70M
773.80M
2.64B
2.94B
2.71B
2.33B
5.75B
6.10B
4.01B
7.33B
Calculated Values
Free Cash Flow TTM
-10.91M
-10.57M
-9.65M
-9.02M
-10.66M
-12.55M
-10.43M
-16.42M
-18.30M
-8.95M
Net Debt
-2.10M
-4.51M
-1.68M
-1.89M
-1.71M
-1.30M
-2.25M
-4.18M
-1.31M
-3.85M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2025-08-25Purchase
Owner: Gaslightwala, Abizer
Title: CEO
Shares: 3,000
Price/Share: $0.90
Value: $2,700.00
Shares Owned: 298,574
Relationship: Director,Officer
Ownership: Direct
2025-06-24Purchase
Owner: Gaslightwala, Abizer
Title: President & CEO
Shares: 5,203
Price/Share: $1.16
Value: $6,035.48
Shares Owned: 277,574
Relationship: Director,Officer
Ownership: Direct
2025-06-20Purchase
Owner: Gaslightwala, Abizer
Title: President & CEO
Shares: 10,000
Price/Share: $1.20
Value: $12,000.00
Shares Owned: 271,428
Relationship: Director,Officer
Ownership: Direct
2025-06-17Purchase
Owner: Gaslightwala, Abizer
Title: President & CEO
Shares: 15,000
Price/Share: $1.20
Value: $18,000.00
Shares Owned: 261,428
Relationship: Director,Officer
Ownership: Direct

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2025-12-31
6.61%
Inst. Shares: 4,452,851
Shares Outstanding: 67,328,129
2025-09-30
7.03%
Inst. Shares: 4,590,056
Shares Outstanding: 65,326,237
2025-06-30
3.47%
Inst. Shares: 2,185,432
Shares Outstanding: 62,943,896

Research Faster.
Invest Smarter.

Akari Therapeutics Plc (AKTX) financial data sourced directly from SEC EDGAR filings — including the latest 10-K annual report, 10-Q quarterly filings, insider transactions (SEC Form 4), institutional ownership (SEC Form 13F), Earning Marker Reaction Heat Map and 50+ calculated financial metrics like Price to Earnings Ratio (P/E), Return on Equity (ROE), Debt to Equity (D/E), Free Cash Flow Per Share (FCF/S), and Return on Invested Capital (ROIC). Unlike platforms that rely on third-party data aggregators, GeminIQ parses raw SEC filings directly — delivering institutional-grade accuracy at a fraction of the cost of Bloomberg Terminal or S&P Capital IQ.